Mizuho analyst Ann Hynes lowered the firm’s price target on Iqvia (IQV) to $190 from $210 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Positive Outlook for IQVIA Holdings Driven by Resilient TAS, Strategic Capital Allocation, and R&D Strength
- Definitive Healthcare downgraded to Neutral from Buy at BTIG
- IQVIA Holdings: Strong Performance and Growth Potential Justify Buy Rating
- IQVIA Holdings: Strong Buy Rating Despite R&D Challenges and Valuation Opportunities
- Iqvia price target lowered to $185 from $255 at UBS